In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD

Bruno Memoli, Giuseppe Grandaliano, Michela Soccio, Loredana Postiglione, Brunella Guida, Vincenzo Bisesti, Pasquale Esposito, Alfredo Procino, Daniela Marrone, Ashour Michael, Michele Andreucci, Francesco Paolo Schena, Giovanni Pertosa

Research output: Contribution to journalArticle

Abstract

Soluble gp130 (sgp130) is a soluble circulating receptor of IL-6 with "antagonistic" biologic activity. It is generated independently by either shedding of the extracellular domain of membrane gp130 or alternative mRNA splicing. This study was addressed to clarify the mechanisms underlying sgp130 synthesis and release in patients who undergo regular dialysis treatment (RDT) using dialytic membranes with different biocompatibility. Two groups of RDT patients were enrolled: 11 patients who were treated with cellulosic membranes (C) and 10 patients who were treated with synthetic membranes (S). Ten healthy subjects constituted the control group. Serum samples and peripheral blood mononuclear cells (PBMC) were harvested in all groups (before dialysis in RDT patients). PBMC were cultured for 24 h in the absence or presence of LPS. The serum levels of sgp130 were significantly higher in C group than in control and S patients (C, 603.1 ± 89.9; control, 396 ± 49.5; S, 423.4 ± 27.7 ng/ml; P <0.01). PBMC from C patients, in the absence of any mitogenic stimulation, released a significantly greater amount of sgp130 as compared with S and control groups (C, 532.6 ± 161.2; S, 332.4 ± 148.6; control, 341.4 ± 125.4 pg/ml; P <0.01). The sgp130 release was positively correlated with the release of both IL-6 (r = 0.336, P <0.05) and sIL-6R receptor (r = 0.324, P <0.05). A significantly higher gp130 gene expression was also observed in unstimulated PBMC from C patients when compared with control and S groups. It is interesting that the expression of the 85-bp exon characteristic of the alternative splicing mRNA for sgp130 was low in all groups. Finally, confocal microscopy analysis showed an increased expression of gp130 on cell surface in unstimulated PBMC from C patients as compared with control and S groups. Our results demonstrate that in patients on RDT with C membranes, the synthesis and release of sgp130 "antagonistic" receptor is significantly increased. This release is seemingly due to a shedding of membrane-bound gp130 receptor. The increased sgp130 release may partially counteract the inflammatory effects caused by IL-6.

Original languageEnglish
Pages (from-to)1099-1107
Number of pages9
JournalJournal of the American Society of Nephrology
Volume16
Issue number4
DOIs
Publication statusPublished - 2005

Fingerprint

Interleukin-6 Receptors
Cytokine Receptor gp130
Chronic Kidney Failure
Dialysis
Blood Cells
Membranes
Control Groups
Alternative Splicing
Interleukin-6
Messenger RNA
Therapeutics
Serum
Confocal Microscopy
Exons
Healthy Volunteers

ASJC Scopus subject areas

  • Nephrology

Cite this

Memoli, B., Grandaliano, G., Soccio, M., Postiglione, L., Guida, B., Bisesti, V., ... Pertosa, G. (2005). In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD. Journal of the American Society of Nephrology, 16(4), 1099-1107. https://doi.org/10.1681/ASN.2004080628

In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD. / Memoli, Bruno; Grandaliano, Giuseppe; Soccio, Michela; Postiglione, Loredana; Guida, Brunella; Bisesti, Vincenzo; Esposito, Pasquale; Procino, Alfredo; Marrone, Daniela; Michael, Ashour; Andreucci, Michele; Schena, Francesco Paolo; Pertosa, Giovanni.

In: Journal of the American Society of Nephrology, Vol. 16, No. 4, 2005, p. 1099-1107.

Research output: Contribution to journalArticle

Memoli, B, Grandaliano, G, Soccio, M, Postiglione, L, Guida, B, Bisesti, V, Esposito, P, Procino, A, Marrone, D, Michael, A, Andreucci, M, Schena, FP & Pertosa, G 2005, 'In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD', Journal of the American Society of Nephrology, vol. 16, no. 4, pp. 1099-1107. https://doi.org/10.1681/ASN.2004080628
Memoli, Bruno ; Grandaliano, Giuseppe ; Soccio, Michela ; Postiglione, Loredana ; Guida, Brunella ; Bisesti, Vincenzo ; Esposito, Pasquale ; Procino, Alfredo ; Marrone, Daniela ; Michael, Ashour ; Andreucci, Michele ; Schena, Francesco Paolo ; Pertosa, Giovanni. / In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD. In: Journal of the American Society of Nephrology. 2005 ; Vol. 16, No. 4. pp. 1099-1107.
@article{e0d08d443e2d4240b641b8ae8113d4fd,
title = "In vivo modulation of soluble {"}antagonistic{"} IL-6 receptor synthesis and release in ESRD",
abstract = "Soluble gp130 (sgp130) is a soluble circulating receptor of IL-6 with {"}antagonistic{"} biologic activity. It is generated independently by either shedding of the extracellular domain of membrane gp130 or alternative mRNA splicing. This study was addressed to clarify the mechanisms underlying sgp130 synthesis and release in patients who undergo regular dialysis treatment (RDT) using dialytic membranes with different biocompatibility. Two groups of RDT patients were enrolled: 11 patients who were treated with cellulosic membranes (C) and 10 patients who were treated with synthetic membranes (S). Ten healthy subjects constituted the control group. Serum samples and peripheral blood mononuclear cells (PBMC) were harvested in all groups (before dialysis in RDT patients). PBMC were cultured for 24 h in the absence or presence of LPS. The serum levels of sgp130 were significantly higher in C group than in control and S patients (C, 603.1 ± 89.9; control, 396 ± 49.5; S, 423.4 ± 27.7 ng/ml; P <0.01). PBMC from C patients, in the absence of any mitogenic stimulation, released a significantly greater amount of sgp130 as compared with S and control groups (C, 532.6 ± 161.2; S, 332.4 ± 148.6; control, 341.4 ± 125.4 pg/ml; P <0.01). The sgp130 release was positively correlated with the release of both IL-6 (r = 0.336, P <0.05) and sIL-6R receptor (r = 0.324, P <0.05). A significantly higher gp130 gene expression was also observed in unstimulated PBMC from C patients when compared with control and S groups. It is interesting that the expression of the 85-bp exon characteristic of the alternative splicing mRNA for sgp130 was low in all groups. Finally, confocal microscopy analysis showed an increased expression of gp130 on cell surface in unstimulated PBMC from C patients as compared with control and S groups. Our results demonstrate that in patients on RDT with C membranes, the synthesis and release of sgp130 {"}antagonistic{"} receptor is significantly increased. This release is seemingly due to a shedding of membrane-bound gp130 receptor. The increased sgp130 release may partially counteract the inflammatory effects caused by IL-6.",
author = "Bruno Memoli and Giuseppe Grandaliano and Michela Soccio and Loredana Postiglione and Brunella Guida and Vincenzo Bisesti and Pasquale Esposito and Alfredo Procino and Daniela Marrone and Ashour Michael and Michele Andreucci and Schena, {Francesco Paolo} and Giovanni Pertosa",
year = "2005",
doi = "10.1681/ASN.2004080628",
language = "English",
volume = "16",
pages = "1099--1107",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "4",

}

TY - JOUR

T1 - In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD

AU - Memoli, Bruno

AU - Grandaliano, Giuseppe

AU - Soccio, Michela

AU - Postiglione, Loredana

AU - Guida, Brunella

AU - Bisesti, Vincenzo

AU - Esposito, Pasquale

AU - Procino, Alfredo

AU - Marrone, Daniela

AU - Michael, Ashour

AU - Andreucci, Michele

AU - Schena, Francesco Paolo

AU - Pertosa, Giovanni

PY - 2005

Y1 - 2005

N2 - Soluble gp130 (sgp130) is a soluble circulating receptor of IL-6 with "antagonistic" biologic activity. It is generated independently by either shedding of the extracellular domain of membrane gp130 or alternative mRNA splicing. This study was addressed to clarify the mechanisms underlying sgp130 synthesis and release in patients who undergo regular dialysis treatment (RDT) using dialytic membranes with different biocompatibility. Two groups of RDT patients were enrolled: 11 patients who were treated with cellulosic membranes (C) and 10 patients who were treated with synthetic membranes (S). Ten healthy subjects constituted the control group. Serum samples and peripheral blood mononuclear cells (PBMC) were harvested in all groups (before dialysis in RDT patients). PBMC were cultured for 24 h in the absence or presence of LPS. The serum levels of sgp130 were significantly higher in C group than in control and S patients (C, 603.1 ± 89.9; control, 396 ± 49.5; S, 423.4 ± 27.7 ng/ml; P <0.01). PBMC from C patients, in the absence of any mitogenic stimulation, released a significantly greater amount of sgp130 as compared with S and control groups (C, 532.6 ± 161.2; S, 332.4 ± 148.6; control, 341.4 ± 125.4 pg/ml; P <0.01). The sgp130 release was positively correlated with the release of both IL-6 (r = 0.336, P <0.05) and sIL-6R receptor (r = 0.324, P <0.05). A significantly higher gp130 gene expression was also observed in unstimulated PBMC from C patients when compared with control and S groups. It is interesting that the expression of the 85-bp exon characteristic of the alternative splicing mRNA for sgp130 was low in all groups. Finally, confocal microscopy analysis showed an increased expression of gp130 on cell surface in unstimulated PBMC from C patients as compared with control and S groups. Our results demonstrate that in patients on RDT with C membranes, the synthesis and release of sgp130 "antagonistic" receptor is significantly increased. This release is seemingly due to a shedding of membrane-bound gp130 receptor. The increased sgp130 release may partially counteract the inflammatory effects caused by IL-6.

AB - Soluble gp130 (sgp130) is a soluble circulating receptor of IL-6 with "antagonistic" biologic activity. It is generated independently by either shedding of the extracellular domain of membrane gp130 or alternative mRNA splicing. This study was addressed to clarify the mechanisms underlying sgp130 synthesis and release in patients who undergo regular dialysis treatment (RDT) using dialytic membranes with different biocompatibility. Two groups of RDT patients were enrolled: 11 patients who were treated with cellulosic membranes (C) and 10 patients who were treated with synthetic membranes (S). Ten healthy subjects constituted the control group. Serum samples and peripheral blood mononuclear cells (PBMC) were harvested in all groups (before dialysis in RDT patients). PBMC were cultured for 24 h in the absence or presence of LPS. The serum levels of sgp130 were significantly higher in C group than in control and S patients (C, 603.1 ± 89.9; control, 396 ± 49.5; S, 423.4 ± 27.7 ng/ml; P <0.01). PBMC from C patients, in the absence of any mitogenic stimulation, released a significantly greater amount of sgp130 as compared with S and control groups (C, 532.6 ± 161.2; S, 332.4 ± 148.6; control, 341.4 ± 125.4 pg/ml; P <0.01). The sgp130 release was positively correlated with the release of both IL-6 (r = 0.336, P <0.05) and sIL-6R receptor (r = 0.324, P <0.05). A significantly higher gp130 gene expression was also observed in unstimulated PBMC from C patients when compared with control and S groups. It is interesting that the expression of the 85-bp exon characteristic of the alternative splicing mRNA for sgp130 was low in all groups. Finally, confocal microscopy analysis showed an increased expression of gp130 on cell surface in unstimulated PBMC from C patients as compared with control and S groups. Our results demonstrate that in patients on RDT with C membranes, the synthesis and release of sgp130 "antagonistic" receptor is significantly increased. This release is seemingly due to a shedding of membrane-bound gp130 receptor. The increased sgp130 release may partially counteract the inflammatory effects caused by IL-6.

UR - http://www.scopus.com/inward/record.url?scp=24344444890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24344444890&partnerID=8YFLogxK

U2 - 10.1681/ASN.2004080628

DO - 10.1681/ASN.2004080628

M3 - Article

C2 - 15716332

AN - SCOPUS:24344444890

VL - 16

SP - 1099

EP - 1107

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 4

ER -